ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,760.49
0.18%
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs Yen
157.3515
-0.03%
Brent Oil
82.14
0.02%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Centessa Pharmaceuticals PLC (CNTA)

  7. Centessa Pharmaceuticals PLC (CNTA) ニュース

CNTA

Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals PLC
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CNTA
日付受信時刻ニュースソース見出しコード企業名
2024/06/1020 : 13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/06/1020 : 00GlobeNewswire Inc.Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business OfficerNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/05/2121 : 45GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/05/1405 : 32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTACentessa Pharmaceuticals PLC
2024/05/1405 : 23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/05/1405 : 10GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
2024/05/0921 : 01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/05/0921 : 00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/04/2410 : 36GlobeNewswire Inc.Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/04/2405 : 17GlobeNewswire Inc.Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/04/2220 : 00GlobeNewswire Inc.Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
2024/03/2905 : 28GlobeNewswire Inc.Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023NASDAQ:CNTACentessa Pharmaceuticals PLC
2024/02/2222 : 00GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/02/0921 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/02/0921 : 00GlobeNewswire Inc.Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia andNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/02/0307 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/02/0307 : 09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/02/0307 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/02/0307 : 04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/02/0307 : 03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/02/0206 : 07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/01/2222 : 00GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/01/0921 : 56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/01/0309 : 46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/01/0309 : 44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/01/0309 : 43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/01/0309 : 41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
2024/01/0309 : 37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
2023/12/1322 : 00GlobeNewswire Inc.Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
2023/12/1121 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
 Showing the most relevant articles for your search:NASDAQ:CNTA

最近閲覧した銘柄

COIN
BLURGBP
Blur
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有